Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- LumiThera raises cash for medical device that uses light to fight vision losson August 16, 2019 at 6:02 am
LumiThera is developing a medical device for people with age-related macular degeneration. Above, a retina with patterns associated with the disease. (National Institute of Health Photo) Medical ...
- Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degenerationon August 15, 2019 at 2:39 am
Drusen are accumulations of extracellular material between the retinal pigment epithelium (RPE) and Bruch’s membrane. They have been considered to result from the normal aging process and may ...
- Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlightson August 14, 2019 at 2:30 am
age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO) were presented at the American Society of Retina Specialists (ASRS ...
- Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019on August 14, 2019 at 2:15 am
the second of the two ongoing adequate and well controlled Phase 3 clinical trials evaluating ONS-5010 against ranibizumab (Lucentis®) for wet age related macular degeneration (wet AMD). The trial is ...
- Novartis teams with interior designer to help wet AMD patientson August 13, 2019 at 10:07 pm
Novartis is teaming up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily impact of wet age-related macular degeneration (wet ...
- Regeneron's Eylea snags prefilled syringe approval as Novartis rival loomson August 13, 2019 at 7:21 am
That's what Regeneron's hoping. The FDA Tuesday approved a new prefilled injector for 2-milligram single doses of Eylea to treat patients with wet age-related macular degeneration (AMD), macular edema ...
- Take care of your eyes nowon August 13, 2019 at 5:17 am
Many studies have shown that exercise and a diet rich in a variety of fruits and vegetables can protect against blinding eye diseases, such as age-related macular degeneration and glaucoma. But you ...
- NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Resultson August 12, 2019 at 1:05 pm
Initiated Phase 1 clinical study of NGM621 for the treatment of dry age-related macular degeneration (AMD)-- --Completed enrollment of 1 mg cohort of 24-week Phase 2 study of NGM282 (aldafermin ...
- Age-Related Macular Degeneration Market Size and share with Innovative Technologies, Key Players and their core competencies by 2023on August 8, 2019 at 9:49 am
(MENAFN - GetNews) A new market study, titled 'Age-Related Macular Degeneration Market Research Report - Global Forecast till 2023' has been featured on Market Research Future. Market Insights ...
via Bing News